BioPharmGuy logo
Sponsored By:
Project Management Now
Purchase the BioPharmGuy data
Sinclair Research
Vtesse is defunct.

Fate: Acquired by Sucampo Pharmaceuticals, April 2017, $200M; Spunout of Cyden Orphan drug accelerator


------------------
If you believe any of this information is incorrect, please let us know.